The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the soluble form of a very complicated name pdgf receptor beta so it's splately derived growth after visit bitter that's a receptor on the pericites and that's reserves the same thing it can be shaded and released into the plasma and into the CSL and that can be measured so basically we know in small vessel disease they are high level of parasite dysfunction and high level of pro-inflammation of the vasculature so that's
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.